The Company has received approval to list its common shares on the Nasdaq Capital Market under the symbol “ACOG” and is ...

“We also announced that the FDA has approved our IDE application allowing us to move ... InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information ...

Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical ...

The FDA has granted Jan123 Orphan ... and its Nasdaq ticker symbol was updated to ALTS. On August 26, 2024, the Company appointed Peter Tassiopoulos as CEO. In October, the Board approved the ...

Change of the Company’s corporate name to Grace Therapeutics, Inc. The Company’s common stock commenced trading under the trading symbol “GRCE” on Nasdaq ... (A-T), for which there are currently no ...

Discover the cutting-edge Apple Intelligence features introduced in iOS 18.1 that enhance user experience and functionality.

the expected nature and timing of the Company's planned FDA submission and related plans for clinical study amendment, whether the Company's cash position will be sufficient to fund operations needed ...

Dr. John Kellum, Chief Medical Officer of Spectral, noted, “Despite a lower enrollment rate for October we continue to see strong performance across trial sites for screening. Our sites are eager to ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised ...

In August, the FDA approved Ascendis Pharma’s Yorvipath ... it snagged the fitting stock symbol “GPCR”). Lead Structure drug candidate GSBR-1290 is currently in mid-stage clinical ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

the expected nature and timing of the Company's planned FDA submission and related plans for clinical study amendment, whether the Company's cash position will be sufficient to fund operations needed ...